Rhabdoid large cell carcinoma of lung, with illustrative immunohistochemical and molecular findings

Applied Immunohistochemistry and Molecular Morphology

Volumn 20, Issue 3, 2012, Pages 208-213

  Dettmer, Matthias ^a,c   Hench, Juergen ^a,b   Pang, Brendan ^b,d   Willi, Niels ^a   Cathomas, Gieri ^a  

^a Cantonal Institute of Pathology   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

EGFR; epithelial mesenchymal transition; large cell carcinoma; lung; rhabdoid

Indexed keywords

ANTIGEN; CYTOKERATIN; DESMIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITHELIAL MEMBRANE ANTIGEN; INTEGRASE; THYROID TRANSCRIPTION FACTOR 1; VIMENTIN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CELL; CASE REPORT; CELL DIFFERENTIATION; COUGHING; CYTOPLASM; EOSINOPHIL; EXON; GENE DELETION; HEMOPTYSIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CARCINOMA; MALE; MUTATION; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RHABDOID TUMOR;

ADENOCARCINOMA; CARCINOMA, LARGE CELL; EPITHELIAL-MESENCHYMAL TRANSITION; EXONS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RHABDOID TUMOR; SEQUENCE ANALYSIS, DNA; TUMOR MARKERS, BIOLOGICAL;

EID: 84859889312     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e31823d8121     Document Type: Article

References (38)

1. Haas JE, Palmer NF, Weinberg AG, et al. Ultrastructure of malignant rhabdoid tumor of the kidney. A distinctive renal tumor of children. Hum Pathol. 1981;12:646-657. (Pubitemid 11012867)
2. Travis B, Müller-Hermelink, Harris, ed. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. World Health Organization. In: P. Kleihues, L.H. Sobin, eds. World Health Organization Classification of Tumours. IARC Press; Lyon: 2004:45-50.
3. Eble JN, Sauter G, Epstein JI, et al. Pathology and genetics of tumours of the urinary system and male genital organs: UICC international union against cancer. In: Kleihues P, Sobin LH, eds. World Health Organization Classification of Tumours. IARC Press; Lyon: 2004:58-59.
4. Versteege I, Sevenet N, Lange J, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature. 1998;394:203-206. (Pubitemid 28325977)
5. Hoot AC, Russo P, Judkins AR, et al. Immunohistochemical analysis of hSNF5/INI1 distinguishes renal and extra-renal malignant rhabdoid tumors from other pediatric soft tissue tumors. Am J Surg Pathol. 2004;28:1485-1491. (Pubitemid 39425515)
6. Colby TV KM, Travis WD. Carcinoid and other neuroendocrine tumors. In: Travis WD, ed. Tumors of Lower Respiratory Tract. Washington DC: Armed Forces Institute of Pathology; 1995:311-540.
7. Cavazza A, Colby TV, Tsokos M, et al. Lung tumors with a rhabdoid phenotype. Am J Clin Pathol. 1996;105:182-188. (Pubitemid 26047478)
8. Shimazaki H, Aida S, Sato M, et al. Lung carcinoma with rhabdoid cells: a clinicopathological study and survival analysis of 14 cases. Histopathology. 2001;38:425-434. (Pubitemid 32863018)
9. Thompson L, Chang B, Barsky SH. Monoclonal origins of malignant mixed tumors (carcinosarcomas). Evidence for a divergent histogenesis. Am J Surg Pathol. 1996;20:277-285. (Pubitemid 26071508)
10. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442-454.
11. Solomon B, Varella-Garcia M, Camidge DR. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol. 2009;4:1450-1454.
12. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693-1703.
13. Kuo J. Electron Microscopy: Methods and Protocols. 2nd ed. New Jersey: Humana Press; 2007.
14. Camidge DR, Kono SA, Flacco A, et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res. 2010;16:5581-5590.
15. Zaravinos A, Mammas IN, Sourvinos G, et al. Molecular detection methods of human papillomavirus (HPV). Int J Biol Markers. 2009;24:215-222.
16. Lim WT, Chuah KL, Leong SS, et al. Assessment of human papillomavirus and Epstein-Barr virus in lung adenocarcinoma. Oncol Rep. 2009;21:971-975.
17. Chan EY. Advances in sequencing technology. Mutat Res. 2005;573: 13-40.
18. Tapia C, Savic S, Bihl M, et al. EGFR mutation analysis in nonsmall- cell lung cancer: experience from routine diagnostics. Patholog. 2009;30:384-392.
19. Saini G, Kumar M, Julka PK, et al. Rhabdoid variant of lung cancer: clinicopathological details of a case and a review of literature. J Cancer Res Ther. 2009;5:54-57.
20. Hiroshima K, Shibuya K, Shimamura F, et al. Pulmonary large cell carcinoma with rhabdoid phenotype. Ultrastruct Pathol. 2003;27:55-59. (Pubitemid 36293156)
21. Tamboli P, Toprani TH, Amin MB, et al. Carcinoma of lung with rhabdoid features. Hum Pathol. 2004;35:8-13. (Pubitemid 38139311)
22. Miyagi J, Tsuhako K, Kinjo T, et al. Rhabdoid tumour of the lung is a dedifferentiated phenotype of pulmonary adenocarcinoma. Histopathology. 2000;37:37-44. (Pubitemid 30496734)
23. ParhamDM, Dias P, Bertorini T, et al. Immunohistochemical analysis of the distribution ofMyoD1 in muscle biopsies of primary myopathies and neurogenic atrophy. Acta Neuropathol. 1994;87:605-611. (Pubitemid 24158415)
24. Dabbs DJ. Diagnostic Immunohistochemistry: Theranostic and Genomic Applications. 3rd ed Saunders Philadelphia: PA 2010.
25. Engel ME, Mouton SC, Emms M. Paediatric rhabdomyosarcoma: MyoD1 demonstration in routinely processed tissue sections using wet heat pretreatment (pressure cooking) for antigen retrieval. J Clin Pathol. 1997;50:37-39. (Pubitemid 27060203)
26. Dasari V, Gallup M, Lemjabbar H, et al. Epithelial-mesenchymal transition in lung cancer: is tobacco the "smoking gun"? Am J Respir Cell Mol Biol. 2006;35:3-9. (Pubitemid 43993148)
27. Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell. 2004;118:277-279. (Pubitemid 39061108)
28. Bremnes RM, Veve R, Hirsch FR, et al. The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis, and prognosis. Lung Cancer. 2002;36:115-124. (Pubitemid 34302891)
29. COSMIC (Catalogue of Somatic Mutations in Cancer), 2011. Available at http://www.sanger.ac.uk/genetics/CGP/cosmic/.
30. Wu M, Zhao J, Song SW, et al. EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer. Lung Cancer. 2010;67:343-347.
31. Zhu JQ, Zhong WZ, Zhang GC, et al. Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals. Cancer Lett. 2008;265:307-317.
32. Moiseyenko VM, Procenko SA, Levchenko EV, et al. High efficacy of first-line gefitinib in non-Asian patients with EGFR-mutated lung adenocarcinoma. Onkologie. 2010;33:231-238.
33. Mitsudomi T. Advances in target therapy for lung cancer. Jpn J Clin Oncol. 2010;40:101-106.
34. Cooper WA, O'Toole S, Boyer M, et al. What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements. Pathology. 2011; 43:103-115.
35. Thomson S, Buck E, Petti F, et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res. 2005;65:9455-9462. (Pubitemid 41508014)
36. Garber K. ALK, lung cancer, and personalized therapy: portent of the future? J Natl Cancer Inst. 2010;102:672-675.
37. Koshiol J, Rotunno M, Gillison ML, et al. Assessment of human papillomavirus in lung tumor tissue. J Natl Cancer Inst. 2011;103: 501-507.
38. Brouchet L, Valmary S, Dahan M, et al. Detection of oncogenic virus genomes and gene products in lung carcinoma. Br J Cancer. 2005;92:743-746. (Pubitemid 40460612)